Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed...
Transcript of Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed...
![Page 1: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/1.jpg)
Galal Galal Galal Galal Adel Adel Adel Adel , 1Bassem RefaatBassem RefaatBassem RefaatBassem Refaat, 1111Mohammed AshshiMohammed AshshiMohammed AshshiMohammed AshshiAhmed Ahmed Ahmed Ahmed
ElElElEl----ShemiShemiShemiShemi1 and Adnan and Adnan and Adnan and Adnan AlZanbagiAlZanbagiAlZanbagiAlZanbagi2
![Page 2: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/2.jpg)
WHO:
• 170 million infected World Wide
• 3-4 NEW infections/Year
It has been classified in to 6 genotypes
• Genotypes1 and 4 in Saudi Arabia
Major cause of liver damage
• Fibrosis/Cirrhosis
• Hepatocellular Carcinoma
![Page 3: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/3.jpg)
![Page 4: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/4.jpg)
Infected
hepatocyte
NKT NK
Inhibit Viral Replication without destroying of
hepatocytes
![Page 5: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/5.jpg)
(Th2)
IL-4
IL-6
IL-10(Th1)
INF-α
IFN-γ
IL-12
![Page 6: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/6.jpg)
(Th1)
(Th2)
IL-4
IL-10
IL-13
ThThThTh2 2 2 2 Response also includes the stimulation of Response also includes the stimulation of Response also includes the stimulation of Response also includes the stimulation of
Transforming Growth Factor (Transforming Growth Factor (Transforming Growth Factor (Transforming Growth Factor (TGF)TGF)TGF)TGF)----ββββ
(Th1)
INF-α
IFN-γ
IL-12
![Page 7: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/7.jpg)
Members of TGF-β superfamily
Originally identified as gonadal proteins
Recently involved in many systems:Recently involved in many systems:
• Growth & differentiation
• Inflammation (Pro or Anti depending on cellular
context)
• Fibrotic diseases
![Page 8: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/8.jpg)
βA-subunit βB-subunit
βA βB
Activin-A
βA
βA
Activin-AB
βA
βB
Activin-B
βB
βB
![Page 9: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/9.jpg)
![Page 10: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/10.jpg)
TGFTGFTGFTGF----β β β β
ActivinActivinActivinActivinfollistatinfollistatinfollistatinfollistatinRegulation
In normal liver In normal liver In normal liver In normal liver (Hepatocyte (Hepatocyte (Hepatocyte (Hepatocyte regeneration)regeneration)regeneration)regeneration)
In Liver In Liver In Liver In Liver disease disease disease disease
(Fibrosis, HCC)(Fibrosis, HCC)(Fibrosis, HCC)(Fibrosis, HCC)
In immune In immune In immune In immune system (Thsystem (Thsystem (Thsystem (Th1 1 1 1 & & & & ThThThTh2 2 2 2 responses)responses)responses)responses)
![Page 11: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/11.jpg)
![Page 12: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/12.jpg)
What are the effects of CHC genotype What are the effects of CHC genotype What are the effects of CHC genotype What are the effects of CHC genotype 1111&&&&4 4 4 4
on serum activinon serum activinon serum activinon serum activin----A & B and follistatinA & B and follistatinA & B and follistatinA & B and follistatinIs there a difference between:Is there a difference between:Is there a difference between:Is there a difference between:
Male and Female patients?Male and Female patients?Male and Female patients?Male and Female patients?
Genotype Genotype Genotype Genotype 1 1 1 1 & & & & 4444????
Do activins & follistatin correlate with:Do activins & follistatin correlate with:Do activins & follistatin correlate with:Do activins & follistatin correlate with:
ProProProPro----inflammatory cytokines (TNFinflammatory cytokines (TNFinflammatory cytokines (TNFinflammatory cytokines (TNF----αααα and ILand ILand ILand IL----6666)?)?)?)?
Liver enzymes?Liver enzymes?Liver enzymes?Liver enzymes?
Liver fibrosis?Liver fibrosis?Liver fibrosis?Liver fibrosis?
![Page 13: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/13.jpg)
![Page 14: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/14.jpg)
80 80 80 80 ParticipantsParticipantsParticipantsParticipants
Control GroupControl GroupControl GroupControl Group40 Healthy Participants
Case GroupCase GroupCase GroupCase Group40 CHC treatment Naïve Patients40 Healthy Participants 40 CHC treatment Naïve Patients
20 Males 20 Females 20 Males 20 Males
10 G1 10 G4
![Page 15: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/15.jpg)
Control GroupControl GroupControl GroupControl Group CaseCaseCaseCase GroupGroupGroupGroup
Patient age ≥ Patient age ≥ Patient age ≥ Patient age ≥ 18 18 18 18 ≤ ≤ ≤ ≤ 45 45 45 45 years.years.years.years. Patient age ≥ Patient age ≥ Patient age ≥ Patient age ≥ 18 18 18 18 ≤ ≤ ≤ ≤ 45 45 45 45 years.years.years.years.
No concurrent No concurrent No concurrent No concurrent acute/chronicacute/chronicacute/chronicacute/chronic diseasediseasediseasedisease HCV RNA positiveHCV RNA positiveHCV RNA positiveHCV RNA positive
Proven fertilityProven fertilityProven fertilityProven fertility No concurrent infection with HBV or HIVNo concurrent infection with HBV or HIVNo concurrent infection with HBV or HIVNo concurrent infection with HBV or HIV
Not taking exogenous hormones/oral contraceptive pills for at Not taking exogenous hormones/oral contraceptive pills for at Not taking exogenous hormones/oral contraceptive pills for at Not taking exogenous hormones/oral contraceptive pills for at
least least least least 3 3 3 3 months prior to enrolmentmonths prior to enrolmentmonths prior to enrolmentmonths prior to enrolmentProven fertilityProven fertilityProven fertilityProven fertility
No history of hospitalisation and no medication for significant No history of hospitalisation and no medication for significant No history of hospitalisation and no medication for significant No history of hospitalisation and no medication for significant Not taking exogenous hormones/oral contraceptive pills Not taking exogenous hormones/oral contraceptive pills Not taking exogenous hormones/oral contraceptive pills Not taking exogenous hormones/oral contraceptive pills No history of hospitalisation and no medication for significant No history of hospitalisation and no medication for significant No history of hospitalisation and no medication for significant No history of hospitalisation and no medication for significant
clinical diseaseclinical diseaseclinical diseaseclinical disease
Not taking exogenous hormones/oral contraceptive pills Not taking exogenous hormones/oral contraceptive pills Not taking exogenous hormones/oral contraceptive pills Not taking exogenous hormones/oral contraceptive pills
for at least for at least for at least for at least 3 3 3 3 months prior to months prior to months prior to months prior to enrolmentenrolmentenrolmentenrolment
laboratory results for their haematological, biochemical and laboratory results for their haematological, biochemical and laboratory results for their haematological, biochemical and laboratory results for their haematological, biochemical and
metabolic parameters were within normal rangemetabolic parameters were within normal rangemetabolic parameters were within normal rangemetabolic parameters were within normal rangeTreatment naïve patientsTreatment naïve patientsTreatment naïve patientsTreatment naïve patients
Compensated liver disease (e.g. no liver cirrhosis, failure Compensated liver disease (e.g. no liver cirrhosis, failure Compensated liver disease (e.g. no liver cirrhosis, failure Compensated liver disease (e.g. no liver cirrhosis, failure
or cancer) & APRI ≤ or cancer) & APRI ≤ or cancer) & APRI ≤ or cancer) & APRI ≤ 1111....2222
Acceptable Acceptable Acceptable Acceptable haematological haematological haematological haematological and biochemical indicesand biochemical indicesand biochemical indicesand biochemical indices
No or controlled type No or controlled type No or controlled type No or controlled type 2 2 2 2 diabetes mellitus and diabetes mellitus and diabetes mellitus and diabetes mellitus and
hypertensionhypertensionhypertensionhypertension
![Page 16: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/16.jpg)
� Liver function parameters & Viral load
� AST/Platelet Ratio Index (APRI) to assess liver fibrosis
� ELISA to measure serum:
� Activin-A
� Activin-B
� Follistatin
� IL-6
� TNF-α
![Page 17: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/17.jpg)
![Page 18: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/18.jpg)
Control Male Control Male Control Male Control Male
(CM)(CM)(CM)(CM)
(n = (n = (n = (n = 20202020))))
Control Female Control Female Control Female Control Female
(CF)(CF)(CF)(CF)
(n = (n = (n = (n = 20202020))))
Male GMale GMale GMale G1 1 1 1 (MG(MG(MG(MG1111))))
(n= (n= (n= (n= 10101010))))
Male G Male G Male G Male G 4 4 4 4
(MG(MG(MG(MG4444))))
(n= (n= (n= (n= 10101010))))
Female GFemale GFemale GFemale G1 1 1 1
(FG(FG(FG(FG1111))))
(n= (n= (n= (n= 10101010))))
Female GFemale GFemale GFemale G4 4 4 4
(FG(FG(FG(FG4444))))
(n= (n= (n= (n= 10101010))))
Age (years)Age (years)Age (years)Age (years) 39 ± 5.4 36 ± 8.3 40.3 ± 4 39.2 ± 5.7 37.9 ± 6.2 34.8 ± 8.8
Viral load at Viral load at Viral load at Viral load at
diagnosis diagnosis diagnosis diagnosis ND ND866784.8 ± 945148.7 ± 1007458.5 ± 988447.8 ±
diagnosis diagnosis diagnosis diagnosis
(IU/mL)(IU/mL)(IU/mL)(IU/mL)
ND ND237056.2 381181.2 318742.4 372327.8
ALP (IU/L)ALP (IU/L)ALP (IU/L)ALP (IU/L) 79.4 ± 21.6 69.2 ± 16.1 125 ± 45.8a,b133.3 ±
35.4a,b130.6 ± 63a,b 124 ± 32.3a,b
ALT (IU/L)ALT (IU/L)ALT (IU/L)ALT (IU/L) 28 ± 11.2 22.2 ± 5.6 89.3 ± 18.1a,b 81.6 ± 19a,b 71.9 ± 22.7a,b 72.8 ± 20.1a,b
AST (IU/L)AST (IU/L)AST (IU/L)AST (IU/L) 21 ± 4.6 22.1 ± 3.1 50.5 ± 14.3a,b 54.6 ± 12.5a,b 57.8 ± 13.4a,b 51.9 ± 15.5a,b
Albumin Albumin Albumin Albumin
(g/dL)(g/dL)(g/dL)(g/dL)4.4 ± 0.24 4.5 ± 0.27 3.7 ± 0.5a,b 3.6 ± 04a,b 3.6 ± 0.4a,b 3.7 ± 0.5a,b
APRIAPRIAPRIAPRI 0.37 ± 0.07 0.36 ± 0.06 0.78 ± 0.3a,b 0.84 ± 0.25a,b 0.85 ± 0.29a,b 0.89 ± 0.32a,b
![Page 19: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/19.jpg)
Control Control Control Control
Male (CM)Male (CM)Male (CM)Male (CM)
(n = (n = (n = (n = 20202020))))
Control Control Control Control
Female Female Female Female
(CF)(CF)(CF)(CF)
(n = (n = (n = (n = 20202020))))
Male GMale GMale GMale G1 1 1 1
(MG(MG(MG(MG1111))))
(n= (n= (n= (n= 10101010))))
Male G Male G Male G Male G 4 4 4 4
(MG(MG(MG(MG4444))))
(n= (n= (n= (n= 10101010))))
Female GFemale GFemale GFemale G1 1 1 1
(FG(FG(FG(FG1111))))
(n= (n= (n= (n= 10101010))))
Female GFemale GFemale GFemale G4 4 4 4
(FG(FG(FG(FG4444))))
(n= (n= (n= (n= 10101010))))
TNFTNFTNFTNF----αααα
(pg/mL)(pg/mL)(pg/mL)(pg/mL)6.1 ± 1.5 5.8 ± 2.1 12..1 ± 2.4a,b 12.5 ± 1.8a,b 11.9 ± 1.6a,b 12.3.± 2.1a,b
ILILILIL----6 6 6 6
(pg/mL)(pg/mL)(pg/mL)(pg/mL)4.1 ± 1.1 3..6 ± 1.01 10.6 ± 1.6a,b 11 ± 1.9a,b 9.9 ± 1.4a,b 10.8.2 ± 1.7a
![Page 20: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/20.jpg)
![Page 21: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/21.jpg)
![Page 22: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/22.jpg)
![Page 23: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/23.jpg)
ActivinActivinActivinActivin----A A A A was strongly and positively correlated was strongly and positively correlated was strongly and positively correlated was strongly and positively correlated with:with:with:with:viral load
APRI
IL-6 and TNF-α
negatively with albumin negatively with albumin
Activin-B showed similar correlationssimilar correlationssimilar correlationssimilar correlations to activin-A but
only in CHC genotype only in CHC genotype only in CHC genotype only in CHC genotype 1111 and it was weaker
No correlation was detected for follistatin
![Page 24: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/24.jpg)
R = 0.836
P = 0.01 X 10-9
![Page 25: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/25.jpg)
R = 0.593
P = 0.0005
![Page 26: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/26.jpg)
R = 0.745
P = 0.03 X 10-6
![Page 27: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/27.jpg)
R = 0.734
P = 0.006 X 10-4
![Page 28: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/28.jpg)
R = -0.586
P = 0.0007
![Page 29: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/29.jpg)
CHC genotype 1 and 4 significantly altered
serum activins and follistatin
The observed significant correlations with viral
load, IL-6 & TNF-α suggests that activins are load, IL-6 & TNF-α suggests that activins are
involved in the host immune response to HC
The correlation of activins with liver enzymes
and APRI suggest that the dysregulation of
activins is associated with liver injury
![Page 30: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/30.jpg)
Could serum activins and follistatin be used as
non-invasive markers for the diagnosis/staging
of liver fibrosis?
Could serum activins and follistatin be used as
prognostic markers for the prediction of CHC
treatment outcome?
![Page 31: Ahmed Mohammed Ashshi 1111, 1, Adel Galal ElEEllEl--- … · 2017-02-01 · Ahmed Mohammed Ashshi1111, Bassem Refaat1, Adel Galal ElEEllEl----ShemiShemi1and Adnan and Adnan AlZanbagiAlZanbagi2](https://reader036.fdocuments.net/reader036/viewer/2022081402/5f0e9c7d7e708231d4401258/html5/thumbnails/31.jpg)